Skip to content

#心血管代谢

Today 0 items
Oct 14Wed
  1. biospace.com48

    Alnylam bulls and bears fight it out after business-shaking guidance cut

    Alnylam cut full-year guidance by about $200 million after second-quarter sales of the TTR silencer Amvuttra in transthyretin-mediated amyloidosis fell short, and its stock has dropped from near $500 to around $250. Analysts at Guggenheim question whether the ATTR-CM opportunity is smaller than expected or whether stabilizers from Pfizer and BridgeBio are becoming preferred, while TD Cowen reiterated a $482 target and BMO argues the cut reflects second-line patient exhaustion. Alnylam is running Phase 3 trials of nucresiran in ATTR-CM and ATTR-PN, and a Phase 3 cardiovascular outcomes trial of zilebesiran in hypertension.

Oct 9Fri
  1. biocentury.com40

    After cardiovascular misses, developers rethink secondary prevention

    Cardiovascular drug developers are reassessing secondary prevention after a series of late-stage failures across IL-6, Lp(a), and Factor XI targets. The failed mechanisms all had substantial human genetic or biological support, exposing the difficulty of translating genetically validated biology into clinical benefit after decades of disease development. Companies including NewAmsterdam Pharma, Regeneron and Forbion are now under pressure to rethink trial design.

Aug 24Mon
  1. Nat Med41

    Global access to different classes of diabetes medicines: a framework for targeted policy actions.

    Researchers led by Felix Teufel propose in Nature Medicine a framework, TARGET-DM, that classifies diabetes medicines by access-related characteristics and matches them to health policies to improve global availability, affordability and accessibility, particularly in low- and middle-income countries. They note that around 530 million people worldwide have type 2 diabetes, only one in five attain glycemic control, and economic losses are estimated at US$10.2 trillion between 2020 and 2050. Unlike HIV, diabetes lacks international coordination and financing mechanisms, leaving medicine access largely to national governments, and even off-patent human insulin remains unaffordable for many patients.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org